Compare VYGR & FVCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYGR | FVCB |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 229.7M |
| IPO Year | 2015 | 2018 |
| Metric | VYGR | FVCB |
|---|---|---|
| Price | $3.76 | $14.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $21.00 | $18.00 |
| AVG Volume (30 Days) | ★ 837.1K | 48.2K |
| Earning Date | 03-09-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.66% |
| EPS Growth | N/A | ★ 47.56 |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $10,135,000.00 | $1,781,000.00 |
| Revenue This Year | $54.19 | $18.73 |
| Revenue Next Year | $20.22 | $7.99 |
| P/E Ratio | ★ N/A | $11.98 |
| Revenue Growth | N/A | ★ 13.87 |
| 52 Week Low | $2.65 | $9.49 |
| 52 Week High | $5.55 | $16.35 |
| Indicator | VYGR | FVCB |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 36.28 |
| Support Level | $3.60 | $13.09 |
| Resistance Level | $4.43 | $15.40 |
| Average True Range (ATR) | 0.33 | 0.41 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 4.37 | 13.42 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, FVCbank which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.